Ephrin-Eph signaling as a potential therapeutic target for the treatment of myocardial infarction

Medical Hypotheses

Volumn 80, Issue 6, 2013, Pages 738-744

  O'Neal, Wesley T ^a   Griffin, William F ^a   Dries Devlin, Jessica L ^b   Kent, Susan D ^a   Chen, Jin ^c,d,e   Willis, Monte S ^f   Virag, Jitka A I ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b University of Minnesota   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN; EPHRIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL INTERACTION; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HEART INFARCTION; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; DRUG EFFECTS; HEART MUSCLE CELL; METABOLISM; MYOCARDIAL INFARCTION; PHYSIOLOGY; WOUND HEALING;

EPHRINS; HUMANS; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, EPH FAMILY; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 84877115398     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.02.024     Document Type: Article

References (117)

1. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:948-954.
2. Trogdon J.G., Finkelstein E.A., Nwaise I.A., Tangka F.K., Orenstein D. The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract 2007, 8:234-242.
3. Heidenreich P.A., Trogdon J.G., Khavjou O.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011, 123:933-944.
4. Kannel W.B. Incidence and epidemiology of heart failure. Heart Fail Rev 2000, 5:167-173.
5. White H.D., Chew D.P. Acute myocardial infarction. Lancet 2008, 372:570-584.
6. Reimer K.A., Jennings R.B. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979, 40:633-644.
7. Jugdutt B.I. Ischemia/Infarction. Heart Fail Clin 2012, 8:43-51.
8. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53:31-47.
9. Keeley E.C., Hillis L.D. Primary PCI for myocardial infarction with ST-segment elevation. N Engl J Med 2007, 356:47-54.
10. Woo Y.J., Panlilio C.M., Cheng R.K., et al. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation 2006, 114:I206-213.
11. Yau T.M., Li G., Weisel R.D., et al. Vascular endothelial growth factor transgene expression in cell-transplanted hearts. J Thorac Cardiovasc Surg 2004, 127:1180-1187.
12. Trescher K., Bernecker O., Fellner B., et al. Inflammation and postinfarct remodeling: overexpression of IkappaB prevents ventricular dilation via increasing TIMP levels. Cardiovasc Res 2006, 69:746-754.
13. Sugano M., Tsuchida K., Hata T., Makino N. In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats. FASEB J 2004, 18:911-913.
14. Abdel-Latif A., Bolli R., Zuba-Surma E.K., Tleyjeh I.M., Hornung C.A., Dawn B. Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J 2008, 156:216-226.
15. French C.J., Taatjes D.J., Sobel B.E. Autophagy in myocardium of murine hearts subjected to ischemia followed by reperfusion. Histochem Cell Biol 2010, 134:519-526.
16. Hamacher-Brady A., Brady N.R., Gottlieb R.A. Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes. J Biol Chem 2006, 281:29776-29787.
17. Shaw J., Kirshenbaum L.A. Molecular regulation of autophagy and apoptosis during ischemic and non-ischemic cardiomyopathy. Autophagy 2008, 4:427-434.
18. Kung G., Konstantinidis K., Kitsis R.N. Programmed necrosis, not apoptosis, in the heart. Circ Res 2011, 108:1017-1036.
19. Kanamori H., Takemura G., Goto K., et al. The role of autophagy emerging in postinfarction cardiac remodelling. Cardiovasc Res 2011, 91:330-339.
20. Pasquale E.B. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008, 133:38-52.
21. Kullander K., Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002, 3:475-486.
22. Brantley D.M., Cheng N., Thompson E.J., et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002, 21:7011-7026.
23. Yamashita T., Ohneda K., Nagano M., et al. Hypoxia-inducible transcription factor-2alpha in endothelial cells regulates tumor neovascularization through activation of ephrinA1. J Biol Chem 2008, 283:18926-18936.
24. Landen C.N., Kinch M.S., Sood A.K. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 2005, 9:1179-1187.
25. McCarron J.K., Stringer B.W., Day B.W., Boyd A.W. Ephrin expression and function in cancer. Future Oncol 2010, 16:165-176.
26. Hafner C., Becker B., Landthaler M., Vogt T. Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol 2006, 19:1369-1377.
27. Dries J.L., Kent S.D., Virag J.A. Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice. J Physiol 2011, 589:1725-1740.
28. Goichberg P., Bai Y., D'Amario D., et al. The ephrinA1-EphA2 system promotes cardiac stem cell migration after infarction. Circ Res 2011, 108:1071-1083.
29. Frangogiannis N.G. Chemokines in ischemia and reperfusion. Thromb Haemostasis 2007, 97:738-747.
30. Frangogiannis N.G. The immune system and cardiac repair. Pharmacol Res 2008, 58:88-111.
31. Bodi V., Sanchis J., Nunez J., et al. Uncontrolled immune response in acute myocardial infarction: unraveling the thread. Am Heart J 2008, 156:1065-1073.
32. Virag J.I., Murry C.E. Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. Am J Pathol 2003, 163:2433-2440.
33. Nian M., Lee P., Khaper N., Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004, 94:1543-1553.
34. Frangogiannis N.G., Entman M.L. Chemokines in myocardial ischemia. Trends Cardiovasc Med 2005, 15:163-169.
35. Kumar D., Jugdutt B.I. Apoptosis and oxidants in the heart. J Lab Clin Med 2003, 142:288-297.
36. Moldovan N.I. Role of monocytes and macrophages in adult angiogenesis: a light at the tunnel's end. J Hematother Stem Cell Res 2002, 11:179-194.
37. Moldovan N.I., Goldschmidt-Clermont P.J., Parker-Thornburg J., Shapiro S.D., Kolattukudy P.E. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res 2000, 87:378-384.
38. Anghelina M., Krishnan P., Moldovan L., Moldovan N.I. Monocytes and macrophages form branched cell columns in matrigel: implications for a role in neovascularization. Stem Cells Dev 2004, 13:665-676.
39. Schulze C.J., Wang W., Suarez-Pinzon W.L., Sawicka J., Sawicki G., Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial [correction of myoctardial] ischemia-reperfusion injury. Circulation 2003, 107:2487-2492.
40. Vanhoutte D., Schellings M., Pinto Y., Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 2006, 69:604-613.
41. Cleutjens J.P., Kandala J.C., Guarda E., Guntaka R.V., Weber K.T. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995, 27:1281-1292.
42. Salih C., McCarthy K.P., Ho S.Y. The fibrous matrix of ventricular myocardium in hypoplastic left heart syndrome: a quantitative and qualitative analysis. Ann Thorac Surg 2004, 77:36-40.
43. Baroldi G. Anatomy and quantification of myocardial cell death. Methods Achiev Exp Pathol 1988, 13:87-113.
44. Holmes J.W., Borg T.K., Covell J.W. Structure and mechanics of healing myocardial infarcts. Annu Rev Biomed Eng 2005, 7:223-253.
45. Sun Y., Kiani M.F., Postlethwaite A.E., Weber K.T. Infarct scar as living tissue. Basic Res Cardiol 2002, 97:343-347.
46. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
47. Egea J., Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol 2007, 17:230-238.
48. Mosch B., Reissenweber B., Neuber C., Pietzsch J. Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol 2010, 2010:135285.
49. Blits-Huizinga C.T., Nelersa C.M., Malhotra A., Liebl D.J. Ephrins and their receptors: binding versus biology. IUBMB Life 2004, 56:257-265.
50. Hamada K., Oike Y., Ito Y., et al. Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells. Arterioscler Thromb Vasc Biol 2003, 23:190-197.
51. Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor. Oncogene 2008, 27:7260-7273.
52. Zhang J., Hughes S. Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 2006, 208:453-461.
53. Holland S.J., Gale N.W., Mbamalu G., Yancopoulos G.D., Henkemeyer M., Pawson T. Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature 1996, 383:722-725.
54. Janes P.W., Griesshaber B., Atapattu L., et al. Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. J Cell Biol 2011, 195:1033-1045.
55. Holzman L.B., Marks R.M., Dixit V.M. A novel immediate-early response gene of endothelium is induced by cytokines and encodes a secreted protein. Mol Cell Biol 1990, 10:5830-5838.
56. Ivanov A.I., Romanovsky A.A. Putative dual role of ephrin-Eph receptor interactions in inflammation. IUBMB Life 2006, 58:389-394.
57. Funk S.D., Yurdagul A., Albert P., et al. EphA2 activation promotes the endothelial cell inflammatory response: a potential role in atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32:686-695.
58. Munoz J.J., Alonso C.L., Sacedon R., et al. Expression and function of the Eph A receptors and their ligands ephrins A in the rat thymus. J Immunol 2002, 169:177-184.
59. Wu J., Luo H. Recent advances on T-cell regulation by receptor tyrosine kinases. Curr Opin Hematol 2005, 12:292-297.
60. Munoz J.J., Alfaro D., Garcia-Ceca J., Alonso C.L., Jimenez E., Zapata A. Thymic alterations in EphA4-deficient mice. J Immunol 2006, 177:804-813.
61. Wohlfahrt J.G., Karagiannidis C., Kunzmann S., et al. Ephrin-A1 suppresses Th2 cell activation and provides a regulatory link to lung epithelial cells. J Immunol 2004, 172:843-850.
62. Wohlfahrt J.G., Kunzmann S., Menz G., et al. T cell phenotype in allergic asthma and atopic dermatitis. Int Arch Allergy Immunol 2003, 131:272-282.
63. Sharfe N., Freywald A., Toro A., Dadi H., Roifman C. Ephrin stimulation modulates T cell chemotaxis. Eur J Immunol 2002, 32:3745-3755.
64. Sharfe N., Nikolic M., Cimpeon L., Van De Kratts A., Freywald A., Roifman C.M. EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions. Mol Immunol 2008, 45:1208-1220.
65. Yang Z., Day Y.J., Toufektsian M.C., et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 2006, 114:2056-2064.
66. Yu Q., Watson R.R., Marchalonis J.J., Larson D.F. A role for T lymphocytes in mediating cardiac diastolic function. Am J Physiol Heart Circ Physiol 2005, 289:H643-H651.
67. Tavernarakis N. Cardiomyocyte necrosis: alternative mechanisms, effective interventions. Biochim Biophys Acta 2007, 1773:480-482.
68. Golstein P., Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 2007, 32:37-43.
69. Abbate A., Bussani R., Biondi-Zoccai G.G., et al. Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. Eur Heart J 2005, 26:2039-2045.
70. Depaepe V., Suarez-Gonzalez N., Dufour A., et al. Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature 2005, 435:1244-1250.
71. Figueroa J.D., Benton R.L., Velazquez I., et al. Inhibition of EphA7 up-regulation after spinal cord injury reduces apoptosis and promotes locomotor recovery. J Neurosci Res 2006, 84:1438-1451.
72. Cheng N., Brantley D., Fang W.B., et al. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 2003, 5:445-456.
73. Jehle J., Staudacher I., Wiedmann F., Schweizer P., Becker R., Katus H., et al. Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid. Br J Pharmacol 2012, 167:1563-1572.
74. Furne C., Ricard J., Cabrera J.R., et al. EphrinB3 is an anti-apoptotic ligand that inhibits the dependence receptor functions of EphA4 receptors during adult neurogenesis. Biochim Biophys Acta 2009, 1793:231-238.
75. Holen H.L., Shadidi M., Narvhus K., Kjosnes O., Tierens A., Aasheim H.C. Signaling through ephrin-A ligand leads to activation of Src-family kinases, Akt phosphorylation, and inhibition of antigen receptor-induced apoptosis. J Leukoc Biol 2008, 84:1183-1191.
76. Yokote H., Fujita K., Jing X., et al. Trans-activation of EphA4 and FGF receptors mediated by direct interactions between their cytoplasmic domains. Proc Natl Acad Sci USA 2005, 102:18866-18871.
77. Dong Y., Undyala V.V., Gottlieb R.A., Mentzer R.M., Przyklenk K. Autophagy: definition, molecular machinery, and potential role in myocardial ischemia-reperfusion injury. J Cardiovasc Pharmacol Ther 2010, 15:220-230.
78. Przyklenk K., Undyala V.V., Wider J., Sala-Mercado J.A., Gottlieb R.A., Mentzer R.M. Acute induction of autophagy as a novel strategy for cardioprotection: getting to the heart of the matter. Autophagy 2011, 7.
79. Komatsu M., Waguri S., Koike M., et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007, 131:1149-1163.
80. Pattingre S., Tassa A., Qu X., et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
81. Gurusamy N., Lekli I., Gorbunov N.V., Gherghiceanu M., Popescu L.M., Das D.K. Cardioprotection by adaptation to ischaemia augments autophagy in association with BAG-1 protein. J Cell Mol Med 2009, 13:373-387.
82. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res 2004, 117:3-32.
83. Wykosky J., Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008, 6:1795-1806.
84. Moon J.J., Lee S.H., West J.L. Synthetic biomimetic hydrogels incorporated with Ephrin-A1 for therapeutic angiogenesis. Biomacromolecules 2007, 8:42-49.
85. Cheng N., Brantley D.M., Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002, 13:75-85.
86. Cheng N., Brantley D.M., Liu H., et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002, 1:2-11.
87. Brantley-Sieders D.M., Fang W.B., Hwang Y., Hicks D., Chen J. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 2006, 66:10315-10324.
88. Nojiri K., Iwakawa M., Ichikawa Y., et al. The proangiogenic factor ephrin-A1 is up-regulated in radioresistant murine tumor by irradiation. Exp Biol Med (Maywood) 2009, 234:112-122.
89. Miao H., Li D.Q., Mukherjee A., et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009, 16:9-20.
90. Brantley-Sieders D.M., Dunaway C.M., Rao M., et al. Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. Cancer Res 2011, 71:976-987.
91. Dunaway C.M., Hwang Y., Lindsley C.W., et al. Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis. Mol Cell Biol 2011, 31:404-416.
92. Macrae M., Neve R.M., Rodriguez-Viciana P., et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005, 8:111-118.
93. Brantley-Sieders D.M., Caughron J., Hicks D., Pozzi A., Ruiz J.C., Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 2004, 117:2037-2049.
94. Okazaki T., Ni A., Baluk P., et al. Capillary defects and exaggerated inflammatory response in the airways of EphA2-deficient mice. Am J Pathol 2009, 174:2388-2399.
95. Deroanne C., Vouret-Craviari V., Wang B., Pouyssegur J. EphrinA1 inactivates integrin-mediated vascular smooth muscle cell spreading via the Rac/PAK pathway. J Cell Sci 2003, 116:1367-1376.
96. Ogita H., Kunimoto S., Kamioka Y., Sawa H., Masuda M., Mochizuki N. EphA4-mediated Rho activation via Vsm-RhoGEF expressed specifically in vascular smooth muscle cells. Circ Res 2003, 93:23-31.
97. Leslie-Barbick J.E., Shen C., Chen C., West J.L. Micron-scale spatially patterned, covalently immobilized vascular endothelial growth factor on hydrogels accelerates endothelial tubulogenesis and increases cellular angiogenic responses. Tissue Eng Part A 2011, 17:221-229.
98. Shaut C.A., Saneyoshi C., Morgan E.A., Knosp W.M., Sexton D.R., Stadler H.S. HOXA13 directly regulates EphA6 and EphA7 expression in the genital tubercle vascular endothelia. Dev Dyn 2007, 236:951-960.
99. Yang P., Yuan W., He J., et al. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: implications for tumor progression and prognosis. Hepatol Res 2009, 39:1169-1177.
100. Dobaczewski M., Gonzalez-Quesada C., Frangogiannis N.G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010, 48:504-511.
101. Cleutjens J.P., Creemers E.E. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction. J Card Fail 2002, 8:S344-S348.
102. Levick S.P., Melendez G.C., Plante E., McLarty J.L., Brower G.L., Janicki J.S. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res 2011, 89:12-19.
103. Brower G.L., Chancey A.L., Thanigaraj S., Matsubara B.B., Janicki J.S. Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol 2002, 283:H518-H525.
104. de Almeida A., Mustin D., Forman M.F., Brower G.L., Janicki J.S., Carver W. Effects of mast cells on the behavior of isolated heart fibroblasts: modulation of collagen remodeling and gene expression. J Cell Physiol 2002, 191:51-59.
105. Arslan F., Smeets M.B., Riem Vis P.W., et al. Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ Res 2011, 108:582-592.
106. Andrassy M., Volz H.C., Igwe J.C., et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008, 117:3216-3226.
107. Oozawa S., Mori S., Kanke T., et al. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ J 2008, 72:1178-1184.
108. Lu Q., Rounds S. Focal adhesion kinase and endothelial cell apoptosis. Microvasc Res 2012, 83:56-63.
109. Miao H., Burnett E., Kinch M., Simon E., Wang B. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat Cell Biol 2000, 2:62-69.
110. Marber M.S., Rose B., Wang Y. The p38 mitogen-activated protein kinase pathway-a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol 2011, 51:485-490.
111. Carter N., Nakamoto T., Hirai H., Hunter T. EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). Nat Cell Biol 2002, 4:565-573.
112. Hakim Z.S., DiMichele L.A., Rojas M., Meredith D., Mack C.P., Taylor J.M. FAK regulates cardiomyocyte survival following ischemia/reperfusion. J Mol Cell Cardiol 2009, 46:241-248.
113. Greenberg R.S., Bernstein A.M., Benezra M., Gelman I.H., Taliana L., Masur S.K. FAK-dependent regulation of myofibroblast differentiation. FASEB J 2006, 20:1006-1008.
114. Mansson-Broberg A., Siddiqui A.J., Genander M., et al. Modulation of ephrinB2 leads to increased angiogenesis in ischemic myocardium and endothelial cell proliferation. Biochem Biophys Res Commun 2008, 373:355-359.
115. Virag J.A., Lust R.M. Coronary artery ligation and intramyocardial injection in a murine model of infarction. J Vis Exp 2011, 52:2581.
116. Frieden L.A., Townsend T.A., Vaught D.B., et al. Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin-A1. Dev Dyn 2010, 239:3226-3234.
117. Genet G., Guilbeau-Frugier C., Honton B., et al. Ephrin-B1 Is a novel specific component of the lateral membrane of the cardiomyocyte and is essential for the stability of cardiac tissue architecture cohesion. Circ Res 2012, 110:688-700.